{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:13Z","timestamp":1794017233193,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.abb.2026.110882","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:30:39Z","timestamp":1779838239000},"page":"110882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis"],"prefix":"10.1016","volume":"782","author":[{"given":"Rui","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mancheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27010450","article-title":"Overcoming therapeutic resistance in triple-negative breast cancer: targeting the undrugged kinome","volume":"27","author":"Lee","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib3","article-title":"Platinum-based systematic therapy in triple-negative breast cancer","volume":"1877","author":"Zhu","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"14","key":"10.1016\/j.abb.2026.110882_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj4009","article-title":"SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1","volume":"10","author":"Deng","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1186\/s12885-019-6278-9","article-title":"Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance","volume":"19","author":"Hill","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12032-023-02237-w","article-title":"Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy","volume":"41","author":"Fu","year":"2023","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.abb.2026.110882_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.abb.2026.110882_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7679","key":"10.1016\/j.abb.2026.110882_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.abb.2026.110882_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455741","article-title":"Broadening horizons: the multifaceted role of ferroptosis in breast cancer","volume":"15","author":"Ge","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.abb.2026.110882_bib11","first-page":"3106","article-title":"SLC7A11\/xCT in cancer: biological functions and therapeutic implications","volume":"10","author":"Lin","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.abb.2026.110882_bib12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"issue":"Pt 1","key":"10.1016\/j.abb.2026.110882_bib13","article-title":"SLC7A11 as a molecular nexus of prognosis, resistance, and therapeutic roadmap in cancer: a systematic review and meta-analysis","volume":"335","author":"Sharma","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.abb.2026.110882_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103304","article-title":"SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4\/6 inhibitors","volume":"76","author":"Cui","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.abb.2026.110882_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.103953.3","article-title":"Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer","volume":"14","author":"Hua","year":"2025","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.abb.2026.110882_bib16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/jpp\/rgae085","article-title":"Dihydroisotanshinone I regulates ferroptosis via PI3K\/AKT pathway to enhance cisplatin sensitivity in lung adenocarcinoma","volume":"77","author":"Li","year":"2025","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s41065-025-00591-5","article-title":"The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis","volume":"162","author":"Yao","year":"2025","journal-title":"Hereditas"},{"key":"10.1016\/j.abb.2026.110882_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2023.105807","article-title":"Hsa-miR-26a-5p improves OSCC sensitivity to ferroptosis by inhibiting SLC7A11","volume":"156","author":"Liang","year":"2023","journal-title":"Arch. Oral Biol."},{"issue":"2","key":"10.1016\/j.abb.2026.110882_bib19","first-page":"184","article-title":"circRNA circSnx12 confers cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p\/SLC7A11 axis","volume":"56","author":"Qin","year":"2023","journal-title":"BMB Rep."},{"key":"10.1016\/j.abb.2026.110882_bib20","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.12659\/MSM.916075","article-title":"Upregulation of long noncoding RNA (lncRNA) X-inactive specific transcript (XIST) is associated with cisplatin resistance in non-small cell lung cancer (NSCLC) by downregulating microRNA-144-3p","volume":"25","author":"Tian","year":"2019","journal-title":"Med. Sci. Monit."},{"issue":"12","key":"10.1016\/j.abb.2026.110882_bib21","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.18632\/aging.101674","article-title":"Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation","volume":"10","author":"Liu","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.abb.2026.110882_bib22","first-page":"3479","article-title":"miR-144-3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2","volume":"40","author":"Yin","year":"2018","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s40001-025-02998-2","article-title":"Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"5","key":"10.1016\/j.abb.2026.110882_bib24","article-title":"Plasma-based microRNA signatures in early diagnosis of breast cancer","volume":"8","author":"Li","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12935-023-03124-0","article-title":"Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics","volume":"23","author":"Carneiro","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.abb.2026.110882_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjms.2024.08.012","article-title":"FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy","volume":"369","author":"Zhu","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.abb.2026.110882_bib27","article-title":"SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9\/GCH1 axis","volume":"292","author":"Song","year":"2024","journal-title":"J. Proteonomics"},{"issue":"4","key":"10.1016\/j.abb.2026.110882_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1039\/D2MO00220E","article-title":"Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches","volume":"19","author":"Yue","year":"2023","journal-title":"Mol. Omics."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","article-title":"Ferroptosis: mechanisms and links with diseases","volume":"6","author":"Yan","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"51","key":"10.1016\/j.abb.2026.110882_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904197","article-title":"Recent progress in ferroptosis inducers for cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.abb.2026.110882_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","article-title":"Lipid peroxidation and ferroptosis: the role of GSH and GPx4","volume":"152","author":"Ursini","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"7664","key":"10.1016\/j.abb.2026.110882_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.abb.2026.110882_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157463","article-title":"Pteris wallichiana bioactives induce ferroptosis via the SLC7A11-GSH-GPX4 axis to directly suppress colorectal cancer","volume":"148","author":"Cao","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.abb.2026.110882_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858462","article-title":"The role of cystine\/glutamate antiporter SLC7A11\/xCT in the pathophysiology of cancer","volume":"12","author":"Jyotsana","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.abb.2026.110882_bib35","first-page":"496","article-title":"SLC7A11 inhibitors represent a promising therapeutic target by facilitating the induction of ferroptosis in breast cancer","volume":"14","author":"Azizi","year":"2025","journal-title":"Int. J. Mol. Cell Med."},{"issue":"2","key":"10.1016\/j.abb.2026.110882_bib36","article-title":"Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms","volume":"1881","author":"Che","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Canc"}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986126001530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986126001530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:19:02Z","timestamp":1780906742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986126001530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0003986126001530"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2026.110882","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-144-3p enhances cisplatin sensitivity in triple-negative breast cancer by targeting SLC7A11 to induce ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2026.110882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110882"}}